Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/16466
Title: Synthesis and pharmacological evaluation of some novel 5-aryl-6- arylamino-1-phenylpyrazolo[3,4-d]pyrimidin-4(5H)-ones as analgesic and anti-inflammatory agents
Authors: Shishoo, Chamanlal J
Pathak, Urvish S
Rathod, Ishwarsinh S
Jain, Kishore S
Nargund, Laxmivenkatesh G
Taranalli, Ashok D
Patel, Hiren
Kumar, Vivek
Shirsath, Vikas S
Issue Date: Jun-1999
Publisher: NISCAIR-CSIR, India
Abstract: A series of novel title compounds 4a-o has been synthesized through two different synthetic routes. While the first involves the condensation of pyrazole o-aminoester 1 with aryl isothiocyanates 2, the second involves cyciocondensation of alkyl isothiourea ethers of sym-diarylthioureas 5 with 1. The compounds have been evaluated for analgesic, as well as, anti-inflammatory activities in rodents. The lead compound, 4c (LM-22835), exhibits analgesic activity comparable to morphine and aspirin at the dose levels of 10 mg/kg p.o. and 100 mg/kg p.o. In the acetic acid induced writhing test, in mice, it has been found to be superior to aspirin in the rat caudal immersion test. Efforts towards optimization of lead compound 4c have resulted in identifying more active compounds. Compounds 4b, 4c, 4e, 4h, 4i and 4o exhibit anti-inflammatory activity superior to aspirin at 100 mg/kg, p.o. in the colton pellet induced granuloma test(rats); compound 4o, is also found to be superior to aspirin when evaluated by the carageenan induced rat paw edema test. Acute toxicity studies reveal that these compounds are non-toxic upto 4.0 g/kg, p.o. in mice. The lead compound, 4c, has been found to be safe and without any untoward effects in the 30, as well as, 60 days chronic toxicity studies in mice.
Page(s): 684-695
URI: http://hdl.handle.net/123456789/16466
Appears in Collections:IJC-B Vol.38B(06) [June 1999]

Files in This Item:
File Description SizeFormat 
IJCB 38B(6) 684-695.pdf2.6 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.